Drug Profile
Fazpilodemab - Genentech
Alternative Names: BFKB-8488A; RG 7992; RO 7040551Latest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Genentech
- Class Bispecific antibodies; Insulin sensitisers
- Mechanism of Action KLB protein inhibitors; Type 1 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 10 Nov 2023 Genentech terminates the phase II BANFF trial in Non-alcoholic steatohepatitis in USA, Belgium, France, Puerto Rico and Spain due to strategic business reason (SC) (NCT04171765) (EudraCT2019-001897-27)
- 10 Nov 2023 Efficacy and adverse event data from the phase II BANFF trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Canada (SC)